

AndrÃ© L SimÃ£o

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5260799/publications.pdf>

Version: 2024-02-01

20
papers

649
citations

840776

11
h-index

888059

17
g-index

23
all docs

23
docs citations

23
times ranked

1255
citing authors

#	ARTICLE	IF	CITATIONS
1	Isolation of Mitochondria from Liver and Extraction of Total RNA and Protein: Analyses of miRNA and Protein Expression. <i>Methods in Molecular Biology</i> , 2021, 2310, 1-15.	0.9	2
2	Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics. <i>Aging</i> , 2021, 13, 23416-23434.	3.1	17
3	RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease. <i>Cut</i> , 2021, 70, 2359-2372.	12.1	56
4	Administration of lactobacillus alleviates experimental NASH by reducing miR-21 in the liver. <i>Journal of Hepatology</i> , 2020, 73, S235.	3.7	0
5	Hepatic RIPK3 signalling differentially modulates lipid metabolism and inflammation in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2020, 73, S672.	3.7	0
6	The role of RIPK3 in non-alcoholic fatty liver disease: a multi-omics perspective. <i>Journal of Hepatology</i> , 2020, 73, S673.	3.7	0
7	miR-21 is increased in patients with NASH-associated HCC and contributes to hepatocarcinogenesis in mice with NAFLD. <i>Journal of Hepatology</i> , 2020, 73, S677-S678.	3.7	1
8	Composite targeting of nuclear receptors protects against diet-induced NAFLD. <i>Journal of Hepatology</i> , 2020, 73, S458.	3.7	0
9	Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning?. <i>Journal of Clinical Medicine</i> , 2020, 9, 1541.	2.4	38
10	Extracellular Vesicles in Non-alcoholic Fatty Liver Disease: Key Players in Disease Pathogenesis and Promising Biomarker Tools. , 2020, , 157-180.		0
11	FRI-278-RIP3-dependent signalling exerts divergent effects on liver steatosis and carcinogenesis in experimental non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2019, 70, e518.	3.7	0
12	Skeletal muscle miR-34a/SIRT1:AMPK axis is activated in experimental and human non-alcoholic steatohepatitis. <i>Journal of Molecular Medicine</i> , 2019, 97, 1113-1126.	3.9	21
13	PS-003-Activation of the miR-34a/SIRT1:AMPK axis contributes for insulin resistance and mitochondrial dysfunction in the NAFLD muscle. <i>Journal of Hepatology</i> , 2019, 70, e7.	3.7	1
14	miRNA-21 ablation protects against liver injury and necroptosis in cholestasis. <i>Cell Death and Differentiation</i> , 2018, 25, 857-872.	11.2	92
15	miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice. <i>Cell Death and Disease</i> , 2017, 8, e2748-e2748.	6.3	78
16	Circulating microRNAs as Potential Biomarkers in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2016, 5, 30.	2.4	77
17	Activation of necroptosis in human and experimental cholestasis. <i>Cell Death and Disease</i> , 2016, 7, e2390-e2390.	6.3	107
18	Inhibition of NF- κ B by deoxycholic acid induces miR-21/PDCD4-dependent hepatocellular apoptosis. <i>Scientific Reports</i> , 2015, 5, 17528.	3.3	24

#	ARTICLE	IF	CITATIONS
19	c-Jun N-Terminal Kinase 1/c-Jun Activation of the p53/MicroRNA 34a/Sirtuin 1 Pathway Contributes to Apoptosis Induced by Deoxycholic Acid in Rat Liver. <i>Molecular and Cellular Biology</i> , 2014, 34, 1100-1120.	2.3	61
20	Revisiting the metabolic syndrome and paving the way for microRNA in non-alcoholic fatty liver disease. <i>FEBS Journal</i> , 2014, 281, 2503-2524.	4.7	55